KDR and non-small cell lung carcinoma: This study indicated that adding apatinib to gefitinib may synergistically inhibit the growth of NSCLC and potentially enhance the efficacy of EGFK‐TKIs monotherapy,30 thus providing the theoretical basis for the combination of VEGFR‐TKIs with EGFR‐TKIs as a novel approach for treating NSCLC.